CCTG

IND223

NCT02905318

IND223

A Phase II Study of Palbociclib, A CDK4/6 Inhibitor, in Patients With Metastatic Castration-Resistant Prostate Cancer

Status:

Recruiting

26459-200.png

II

Phase

Line of Therapy.png

2nd+

Line of Therapy

Disease Stage.png

Advanced / Metastatic

Disease Stage

Target.png

Biomarker(s)

N/A

Investigational

Product

Palbociclib

CDK4/6 Inhibitor (p.o.)

Treatment Arms

o Experimental: Palbociclib